SHANGHAI FOSUN PHARMACEUTICAL Aktie

 

Fosun Pharma (02196.HK) announced that its subsidiary, Shanghai Henlius Biotech and its holding subsidiary Henlius, have received approval from the National Medical Products Administration for HLX319 (pertuzumab-trastuzumab injection (subcutaneous) biosimilar) to conduct a Phase I clinical trial for neoadjuvant therapy in HER2-p......

Fosun Pharma (02696.HK) announced that the National Medical Products Administration (NMPA) has approved the Phase 1 clinical trial application (INDs) for its independently developed biosimilar injection HLX319 (subcutaneous injection) of pertuzumab-trastuzumab. The company plans to conduct related clinical trials in China once c......

Um den gesamten Artikel unter aastocks.com zu lesen, klicken Sie bitte auf die Überschrift...

Fosun Pharma (02696.HK) announced that the Phase 1 clinical trial application (IND) for its independently developed HLXTEHAase02 (recombinant human hyaluronidase injection) has been approved by the National Medical Products Administration (NMPA). The company plans to conduct the related clinical trials within mainland China (exc......

Fosun Pharma (02696.HK) announced that its independently developed Slulitinib Injection (HANSIZHUANG, HETRONIFLY) has received a positive opinion from the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP). The recommendation is to approve HANSIZHUANG in combination with fluoropyrimidine and platin......

Um den gesamten Artikel unter aastocks.com zu lesen, klicken Sie bitte auf die Überschrift...

Um den gesamten Artikel unter aastocks.com zu lesen, klicken Sie bitte auf die Überschrift...

Innovation and Globalization Propel Fosun Pharma's High-Quality Growth SHANGHAI, March 24, 2026 /PRNewswire/ -- On 24 March, 2026, Fosun Pharma ("the company", stock code: 600196.SH; 02196.HK), an innovation-driven global pharmaceutical and healthcare group, announced its 2025 annual......

A unit of Fosun Pharma has struck a US$1.55 billion deal to license its home-grown cancer drug to Japan's Eisai, adding to a wave of out-licensing agreements that are channelling billions of dollars into Chinese novel drug development. The deal comes as Chinese novel drug makers are having more say in how their new medicines are developed with global partners, shifting from simple one-off licensing fees, where a company is paid for granting rights to its drug, to long-term collaborations. Under......

The board of Shanghai Fosun Pharmaceutical approved the spin-off and Hong Kong listing of its vaccine unit, aiming to bolster the business as biotechnology shares continue to outperform in the city's stock market. The board cleared the proposed spin-off of Fosun Adgenvax (Chengdu) Biopharmaceutical for a Hong Kong initial public offering (IPO) on Thursday, according to a late filing by Fosun Pharma, whose shares are listed in Shanghai and Hong Kong. The filing did not disclose the planned IPO......

Insilico Medicine and Hygtia Therapeutics, an incubatee of Shenzhen Pengfu Fund of Fosun Health Capital and Fosun Pharma, have entered into an exclusive license and co-development collaboration to advance ISM8969 worldwide. Under the agreement, both parties hold 50% worldwide rights, and......

US-Pharmariesen verlieren Patentschutz im Marktwert von Milliarden Dollar. Chinesische Biotechs liefern Ersatz. Was heißt das für den globalen Pharma-Markt?...

Irina Zhou's five-year-old cat has gained about a kilogram every year for the past three years. She knows the extra weight puts her pet at risk of obesity-related diseases and could even shorten his life. “My parents just can't bear to see the cat go hungry,” the 29-year-old Zhou said. “If the weight starts to affect his health, I might consider trying weight-loss medicines for him.” The idea of using obesity drugs for pets drew public attention after Fosun Pharma's unit Yao Pharma signed a......

Playing catch-up in the anti-obesity business, Pfizer has bought global rights to an oral weight-loss drug from Fosun Pharma in another big licensing deal Key Takeaways:    By Molly Wen It's becoming a familiar story: the Chinese drugs industry has signed another licensing deal with Big Pharma to fast track a weight-loss treatment. This time..... The post Lagging in the weight-loss market? Take Fosun's GLP-1 pill appeared first on Bamboo Works....

Shanghai Fosun Pharmaceutical Group Co. announced plans to acquire a controlling stake in a Chinese company that developed the country's first indigenous therapy for Alzheimer's disease only to wind up later suspending sales and production....

Boston, MA (www.aktiencheck.de) - Pfizer-Aktienanalyse von Leerink Partners: David Risinger, Analyst von Leerink Partners, stuft die Aktie von Pfizer Inc. (ISIN: US7170811035, WKN: 852009, Ticker-Symbol: PFE, NYSE-Symbol: PFE) mit "market perform" ein. Pfizer habe am 9. Dezember 2025 bekannt gegeben, eine exklusive globale Kollaborations- und Lizenzvereinbarung mit YaoPharma, einer Tochtergesellschaft von Fosun Pharma, für YP05002 abgeschlossen zu haben - einen GLP-1RA-Small-Molecule-Kandidaten in Phase 1. [mehr]...

US pharmaceutical behemoth Pfizer has agreed to pay up to US$2.1 billion to Shanghai-based Fosun Pharma's unit Yao Pharma for an experimental oral obesity drug, underscoring the growing trend of Chinese drug makers selling early-stage assets to global multinationals. Under the licensing agreement, Yao Pharma would grant Pfizer an exclusive worldwide licence for the development, use, manufacturing and commercialisation of oral small-molecule drugs known as GLP-1 receptor agonists, including......

FOSUN PHARMA (02196.HK) signed a US$2.1 billion collaboration agreement with Pfizer (PFE.US) for its preclinical small molecule GLP-1 drug. Due to Pfizer's active involvement and long-term arrangement in the GLP-1 field, this collaboration gives YP05002 a leading position, CLSA released a research report saying. Compared to ......

Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...

Pfizer Inc. has entered into an exclusive global collaboration and licensing deal with a unit of Shanghai Fosun Pharmaceutical (Group) Co. for an early-stage weight-loss drug....